1. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.
- Author
-
Meyer, Matthew, Kirmess, Kristopher, Eastwood, Stephanie, Wente-Roth, Traci, Irvin, Faith, Holubasch, Mary, Venkatesh, Venky, Fogelman, Ilana, Monane, Mark, Hanna, Lucy, Rabinovici, Gil, Siegel, Barry, Whitmer, Rachel, Apgar, Charles, Bateman, Randall, Holtzman, David, Irizarry, Michael, Verbel, David, Sachdev, Pallavi, Ito, Satoshi, Contois, John, Yarasheski, Kevin, Braunstein, Joel, Verghese, Philip, and West, Tim
- Subjects
Alzheimers ,amyloid beta ,blood biomarker ,clinical validity ,diagnostic ,p‐tau217 ,Humans ,Amyloid beta-Peptides ,Female ,Male ,tau Proteins ,Alzheimer Disease ,Aged ,Algorithms ,Positron-Emission Tomography ,Peptide Fragments ,Brain ,Biomarkers ,Mass Spectrometry ,Middle Aged ,Aged ,80 and over ,ROC Curve - Abstract
BACKGROUND: With the availability of disease-modifying therapies for Alzheimers disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receiving treatment. METHODS: High-throughput, mass spectrometry-based assays were used to measure %p-tau217 and amyloid beta (Aβ)42/40 ratio in blood samples from 583 individuals with suspected AD (53% positron emission tomography [PET] positive by Centiloid > 25). An algorithm (PrecivityAD2 test) was developed using these plasma biomarkers to identify brain amyloidosis by PET. RESULTS: The area under the receiver operating characteristic curve (AUC-ROC) for %p-tau217 (0.94) was statistically significantly higher than that for p-tau217 concentration (0.91). The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2, was 0.94, yielding 88% agreement with amyloid PET. Diagnostic performance of the APS2 was similar by ethnicity, sex, age, and apoE4 status. DISCUSSION: The PrecivityAD2 blood test showed strong clinical validity, with excellent agreement with brain amyloidosis by PET.
- Published
- 2024